Q3 2011 · —
Revenue$73.29M$73.29M ±0.0% vs Q3 2010+13.5% vs Q2 2011
Net Income$32.48M$32.48M ±0.0% vs Q3 2010−2.2% vs Q2 2011
EPS Diluted$0.69$0.69 ±0.0% vs Q3 2010−2.8% vs Q2 2011
Gross Profit$68,315,000±0.0%
Operating Income$33,704,000+133.4%
Operating Cash Flowderived$46,053,000+149.1%
Free Cash Flowderived$45,691,000+151.5%
Margins · derived
Gross margin93.2%±0.0 pt vs Q3 2010
Operating margin46.0%+26.3 pt vs Q3 2010
Net margin44.3%±0.0 pt vs Q3 2010
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q3 2011 | Q3 2010 |
|---|---|---|
| Revenue | $73.29M | $73.29M |
| Net Income | $32.48M | $32.48M |
| EPS Diluted | $0.69 | $0.69 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Jazz Pharmaceuticals plc · CIK 1232524 · Engraved from SEC EDGAR